QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN
- 31 March 2006
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 34 (7), 1136-1144
- https://doi.org/10.1124/dmd.105.008664
Abstract
Quinacrine (QA), an antimalarial drug used for over seven decades, has been found to have potent antiprion activity in vitro. To determine whether QA can be used to treat prion diseases, we investigated its metabolism and ability to traverse the blood-brain barrier in mice. In vitro and in vivo, we identified by liquid chromatography-tandem mass spectrometry the major metabolic pathway of QA as N-desethylation and compared our results with an authentic reference compound. The major human cytochrome (P450) isoforms involved in QA mono-desethylation were identified as CYP3A4/5 by using specific chemical and antibody inhibition as well as cDNA-expressed P450 studies. QA transport from the basolateral to apical side in multidrug resistance protein 1 gene (MDR1)-transfected Madin-Darby canine kidney (MDCK) cells was markedly greater than in control MDCK cells and was inhibited by the potent P-glycoprotein (P-gp) inhibitor GG918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-iso-1-quinolynyl)-ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamine). In MDR1-knockout (KO) mice, QA brain levels were 6 to 9 times higher after a single i.v. dose of 2 mg/kg QA and 49 times higher after multiple oral doses of 10 mg/kg/day QA for 7 days, compared with those in wild-type (WT) FVB mice. In contrast, the QA levels in plasma, liver, spleen, and kidney were similar after a single 2 mg/kg i.v. dose and <2 times greater after 10 mg/kg oral doses in MDR1-KO mice compared with WT mice. These results indicate that P-gp plays a critical role in transporting QA from the brain.Keywords
This publication has 17 references indexed in Scilit:
- A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapieBritish Journal of Pharmacology, 2005
- HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMESDrug Metabolism and Disposition, 2004
- Combined Quinacrine and Chlorpromazine Therapy in Fatal Familial InsomniaClinical Neuropharmacology, 2004
- Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal ModelsJournal of Virology, 2004
- Uptake and Efflux of Quinacrine, a Candidate for the Treatment of Prion Diseases, at the Blood-Brain BarrierCellular and Molecular Neurobiology, 2004
- Evaluation of Quinacrine Treatment for Prion DiseasesJournal of Virology, 2003
- Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease modelAnnals of Neurology, 2002
- Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein AccumulationJournal of Virology, 2000
- The acridine ring selectively intercalated into a DNA helix at various types of abasic sites: double strand formation and photophysical propertiesNucleic Acids Research, 1996
- Effect of Aliphatic Side-Chain Substituents on the Antimalarial Activity and on the Metabolism of Primaquine Studied Using Mitochondria and Microsome PreparationsPharmaceutical Research, 1990